Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HUC3-053
- Development stage
- Phase 3
- Modality
- Small Molecules
- Administration
- Ophthalmic
01
Overview
HUC3-053 is an investigational drug being evaluated for the treatment of dry eye syndrome. It is currently undergoing a multi-center, randomized, double-blinded, non-inferiority Phase 3 clinical trial comparing its efficacy and safety to Hyalein Mini Drops in patients with dry eye syndrome. The specific mechanism of action for HUC3-053 has not been disclosed in public sources[1][2][4]. No information about its molecular modality or active ingredient has been published.
- Brand names
- Hyalein MiniHialid Mini
- Other names
- sodium hyaluronate ophthalmic solutionHyalein Mini Drops
02
Targets
CD44 (CD44 antigen)FnBPA (Fibronectin-binding protein A)
Beyond the preview
Go deeper on HUC3-053.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HUC3-053.